AVENUE THERAPEUTICS, INC. (ATXI)
2025-06-30 | ||||
---|---|---|---|---|
Other revenue | 1,404 | |||
Research and development | 192 | |||
General and administrative | 915 | |||
Total operating expenses | 1,107 | |||
Income (loss) from operations | 297 | |||
Interest income | 31 | |||
Change in fair value of warrant liabilities | -1 | |||
Loss on settlement of common stock warrant liabilities | - | |||
Total other income (expense) | 32 | |||
Net income (loss) | 329 | |||
Net loss attributable to non-controlling interests | -6 | |||
Net income (loss) attributable to avenue | 335 | |||
Weighted average number of common shares outstanding, basic and diluted (in shares) | 3,183,558 |